{"classes":[{"categories":[{"measurements":[{"comment":"Insufficient data values to calculate coefficient of variation.","groupId":"OG000","spread":"NA","value":"2712"},{"groupId":"OG001","spread":"82.5","value":"3207"},{"groupId":"OG002","spread":"39.4","value":"12328"},{"groupId":"OG003","spread":"26.9","value":"14107"},{"groupId":"OG004","spread":"89.2","value":"16926"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"8"},{"groupId":"OG003","value":"9"},{"groupId":"OG004","value":"7"}],"units":"Participants"}],"title":"Day 1"},{"categories":[{"measurements":[{"comment":"Insufficient data values to calculate coefficient of variation.","groupId":"OG000","spread":"NA","value":"6401"},{"groupId":"OG001","spread":"133.8","value":"4388"},{"groupId":"OG002","spread":"48.5","value":"27389"},{"groupId":"OG003","spread":"38.3","value":"30823"},{"groupId":"OG004","spread":"101.6","value":"33070"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"6"},{"groupId":"OG003","value":"7"},{"groupId":"OG004","value":"5"}],"units":"Participants"}],"title":"Day 15"}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"8"},{"groupId":"OG003","value":"9"},{"groupId":"OG004","value":"7"}],"units":"Participants"}],"description":"AUC0-24 is defined as the area under the concentration-time curve from Time 0 to 24 hours after a dose. Plasma metabolite M1 was measured using validated chiral liquid chromatography-mass spectrometry methods (LC-MS/MS). The lower limit of quantification (LLOQ) in plasma was 10.0 ng/mL.","dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"Participants received a single dose of 7.5 mg CC-223 on Day -1, then daily dosing of 7.5 mg CC-223 for 28 days beginning on Day 1. Participants received subsequent cycles consisting of 28-day continuous dosing without rest between cycles for as long as they derived benefit from treatment as judged by the investigator.","id":"OG000","title":"Part A: CC-223 7.5 mg"},{"description":"Participants received a single dose of 15 mg CC-223 on Day -1, then daily dosing of 15 mg CC-223 for 28 days beginning on Day 1. Participants received subsequent cycles consisting of 28-day continuous dosing without rest between cycles for as long as they derived benefit from treatment as judged by the investigator.","id":"OG001","title":"Part A: CC-223 15 mg"},{"description":"Participants received a single dose of 30 mg CC-223 on Day -1, then daily dosing of 30 mg CC-223 for 28 days beginning on Day 1. Participants received subsequent cycles consisting of 28-day continuous dosing without rest between cycles for as long as they derived benefit from treatment as judged by the investigator.","id":"OG002","title":"Part A: CC-223 30 mg"},{"description":"Participants received a single dose of 45 mg CC-223 on Day -1, then daily dosing of 45 mg CC-223 for 28 days beginning on Day 1. Participants received subsequent cycles consisting of 28-day continuous dosing without rest between cycles for as long as they derived benefit from treatment as judged by the investigator.","id":"OG003","title":"Part A: CC-223 45 mg"},{"description":"Participants received a single dose of 60 mg CC-223 on Day -1, then daily dosing of 60 mg CC-223 for 28 days beginning on Day 1. Participants received subsequent cycles consisting of 28-day continuous dosing without rest between cycles for as long as they derived benefit from treatment as judged by the investigator.","id":"OG004","title":"Part A: CC-223 60 mg"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"All treated participants with available pharmacokinetic data in Part A.","reportingStatus":"POSTED","timeFrame":"0 to 24 hours post-dose on Day -1 and Day 15","title":"Area Under the Concentration Time-Curve From 0-24 Hours After a Dose (AUC0-24) for Metabolite M1","type":"SECONDARY","unitOfMeasure":"ng*h/mL"}